Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
21 Februar 2023 - 02:25PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2023
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1 .
Annual Financial Report
21
February 2023 11:00 GMT
Annual Financial Report
AstraZeneca
PLC (the Company) announced today the publication of its Annual
Report and Form 20-F Information 2022 (the Annual
Report).
A copy of the Annual Report will be submitted to
the National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Annual Report is also available on the
Company's website www.astrazeneca.com.
The
Annual Report will be dispatched to shareholders in due
course.
The
Company's Annual General Meeting (AGM) will take place on 27 April
2023. The Notice of AGM and Shareholders' Circular will be
published and distributed to shareholders in due
course.
EXPLANATORY NOTE
For
the purposes of complying with the Disclosure and Transparency
Rules, the Annual Report being submitted to the National Storage
Mechanism, contains the following regulated information in unedited
form:
-
The principal risks and uncertainties facing
the Company;
-
The Directors' responsibility statement made in
respect of the Financial Statements and Directors' Report contained
in the Annual Report; and
-
A statement regarding related party
transactions.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
21 February 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2023 bis Jun 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2022 bis Jun 2023
